根据双方协议,Rtw将有权获得Candel Therapeutics, Inc.旗下产品Aglatimagene在美国市场的年度净销售额的分层个位数百分比作为分成,但此项分成设有上限。
根据双方协议,Rtw将有权获得Candel Therapeutics, Inc.旗下产品Aglatimagene在美国市场的年度净销售额的分层个位数百分比作为分成,但此项分成设有上限。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.